These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21904603)

  • 1. Dietary α-eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor-γ.
    Lewis SN; Brannan L; Guri AJ; Lu P; Hontecillas R; Bassaganya-Riera J; Bevan DR
    PLoS One; 2011; 6(8):e24031. PubMed ID: 21904603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of PPARγ and δ by dietary punicic acid ameliorates intestinal inflammation in mice.
    Bassaganya-Riera J; DiGuardo M; Climent M; Vives C; Carbo A; Jouni ZE; Einerhand AW; O'Shea M; Hontecillas R
    Br J Nutr; 2011 Sep; 106(6):878-86. PubMed ID: 21736821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell PPARγ is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD.
    Guri AJ; Evans NP; Hontecillas R; Bassaganya-Riera J
    J Nutr Biochem; 2011 Sep; 22(9):812-9. PubMed ID: 21109419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
    Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
    Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipocalin 2 links inflammation and ankylosis in the clinical overlap of inflammatory bowel disease (IBD) and ankylosing spondylitis (AS).
    Lin A; Inman RD; Streutker CJ; Zhang Z; Pritzker KPH; Tsui HW; Tsui FWL
    Arthritis Res Ther; 2020 Mar; 22(1):51. PubMed ID: 32188494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARgamma and IBD)].
    Rousseaux C; Desreumaux P
    J Soc Biol; 2006; 200(2):121-31. PubMed ID: 17151549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phytochemical drug candidates for the modulation of peroxisome proliferator-activated receptor γ in inflammatory bowel diseases.
    Venkataraman B; Ojha S; Belur PD; Bhongade B; Raj V; Collin PD; Adrian TE; Subramanya SB
    Phytother Res; 2020 Jul; 34(7):1530-1549. PubMed ID: 32009281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor angiogenesis suppression by alpha-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via peroxisome proliferator-activated receptor gamma.
    Tsuzuki T; Kawakami Y
    Carcinogenesis; 2008 Apr; 29(4):797-806. PubMed ID: 18174233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhodanine derivatives as novel peroxisome proliferator-activated receptor gamma agonists.
    Liu Q; Zhang YY; Lu HL; Li QY; Zhou CH; Wang MW
    Acta Pharmacol Sin; 2007 Dec; 28(12):2033-9. PubMed ID: 18031620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation.
    Hontecillas R; O'Shea M; Einerhand A; Diguardo M; Bassaganya-Riera J
    J Am Coll Nutr; 2009 Apr; 28(2):184-95. PubMed ID: 19828904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 13-Oxo-ODE is an endogenous ligand for PPARgamma in human colonic epithelial cells.
    Altmann R; Hausmann M; Spöttl T; Gruber M; Bull AW; Menzel K; Vogl D; Herfarth H; Schölmerich J; Falk W; Rogler G
    Biochem Pharmacol; 2007 Aug; 74(4):612-22. PubMed ID: 17604003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease.
    Adachi M; Kurotani R; Morimura K; Shah Y; Sanford M; Madison BB; Gumucio DL; Marin HE; Peters JM; Young HA; Gonzalez FJ
    Gut; 2006 Aug; 55(8):1104-13. PubMed ID: 16547072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Peroxisome Proliferator-activated Receptor (PPAR)γ Agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate Exerts Anti-Inflammatory Effects in Colitis.
    Choo J; Lee Y; Yan XJ; Noh TH; Kim SJ; Son S; Pothoulakis C; Moon HR; Jung JH; Im E
    J Biol Chem; 2015 Oct; 290(42):25609-19. PubMed ID: 26342083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of glucocorticoid receptor activation on anti-inflammatory effect induced by peroxisome proliferator-activated receptor γ agonist in mice.
    Yamamoto A; Kakuta H; Sugimoto Y
    Int Immunopharmacol; 2014 Sep; 22(1):204-8. PubMed ID: 24975659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
    Gani OA
    Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
    Pedersen G
    Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of peroxisome proliferator-activated receptor gamma (PPAR γ) by conjugated fatty acid in obesity and inflammatory bowel disease.
    Yuan G; Chen X; Li D
    J Agric Food Chem; 2015 Feb; 63(7):1883-95. PubMed ID: 25634802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARgamma as a new therapeutic target in inflammatory bowel diseases.
    Dubuquoy L; Rousseaux C; Thuru X; Peyrin-Biroulet L; Romano O; Chavatte P; Chamaillard M; Desreumaux P
    Gut; 2006 Sep; 55(9):1341-9. PubMed ID: 16905700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combined ligand- and structure-based virtual screening protocol identifies submicromolar PPARγ partial agonists.
    Vidović D; Busby SA; Griffin PR; Schürer SC
    ChemMedChem; 2011 Jan; 6(1):94-103. PubMed ID: 21162086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency.
    Lytle C; Tod TJ; Vo KT; Lee JW; Atkinson RD; Straus DS
    Inflamm Bowel Dis; 2005 Mar; 11(3):231-43. PubMed ID: 15735429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.